CN107847480B - 呼吸性疾病的治疗 - Google Patents

呼吸性疾病的治疗 Download PDF

Info

Publication number
CN107847480B
CN107847480B CN201680026219.6A CN201680026219A CN107847480B CN 107847480 B CN107847480 B CN 107847480B CN 201680026219 A CN201680026219 A CN 201680026219A CN 107847480 B CN107847480 B CN 107847480B
Authority
CN
China
Prior art keywords
inhibitor
subject
lung
casein kinase
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026219.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107847480A (zh
Inventor
阿拉斯泰尔·斯图尔特
克里斯汀·基南
特鲁迪·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianli Biotechnology Private Ltd
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901032A external-priority patent/AU2015901032A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Priority to CN202110636730.0A priority Critical patent/CN113350352B/zh
Priority to CN202110650935.4A priority patent/CN113350353A/zh
Publication of CN107847480A publication Critical patent/CN107847480A/zh
Application granted granted Critical
Publication of CN107847480B publication Critical patent/CN107847480B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680026219.6A 2015-03-23 2016-03-23 呼吸性疾病的治疗 Active CN107847480B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110636730.0A CN113350352B (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗
CN202110650935.4A CN113350353A (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901032A AU2015901032A0 (en) 2015-03-23 Treatment of respiratory diseases
AU2015901032 2015-03-23
PCT/AU2016/050209 WO2016149756A1 (en) 2015-03-23 2016-03-23 Treatment of respiratory diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110650935.4A Division CN113350353A (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗
CN202110636730.0A Division CN113350352B (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗

Publications (2)

Publication Number Publication Date
CN107847480A CN107847480A (zh) 2018-03-27
CN107847480B true CN107847480B (zh) 2021-06-25

Family

ID=56976881

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680026219.6A Active CN107847480B (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗
CN202110636730.0A Active CN113350352B (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗
CN202110650935.4A Pending CN113350353A (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110636730.0A Active CN113350352B (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗
CN202110650935.4A Pending CN113350353A (zh) 2015-03-23 2016-03-23 呼吸性疾病的治疗

Country Status (6)

Country Link
US (4) US10722513B2 (enExample)
EP (2) EP4591936A3 (enExample)
JP (2) JP6827948B2 (enExample)
CN (3) CN107847480B (enExample)
FI (1) FI3273955T3 (enExample)
WO (1) WO2016149756A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
JP2016193861A (ja) * 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
ES2902885T3 (es) * 2017-02-01 2022-03-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
WO2019090405A1 (pt) * 2017-11-11 2019-05-16 Carvalho Junior Mario Virgilio De Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza
CN113260616B (zh) * 2018-11-07 2025-05-02 天莅生物技术有限公司 用于治疗呼吸系统疾病的新型化合物
KR102253324B1 (ko) * 2019-11-27 2021-05-18 단디바이오사이언스 주식회사 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
AR122711A1 (es) 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
TW202246233A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
CA3217735A1 (en) * 2021-05-03 2022-11-10 David A. Bullough Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用
WO2024091485A1 (en) * 2022-10-25 2024-05-02 The Regents Of The University Of California Compositions and methods for treating or preventing pulmonary fibrosis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103240A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1)
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101616925A (zh) * 2007-02-02 2009-12-30 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途
CN102686580A (zh) * 2009-10-28 2012-09-19 美国辉瑞有限公司 用作酪蛋白激酶抑制剂的咪唑衍生物
WO2012080727A4 (en) * 2010-12-14 2012-10-26 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
EP2589385A1 (en) * 2011-11-03 2013-05-08 Fundación Centro Nacional de Investigaciones Oncológicas Triple combination for the treatment of cancer
WO2014018691A1 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
CN103784451A (zh) * 2012-10-31 2014-05-14 无锡蕾明视康科技有限公司 一种治疗抑郁症的药物
WO2014100533A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
WO2014100540A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
MX9705296A (es) 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CN1968716A (zh) * 2003-01-09 2007-05-23 阿里泽克药品公司 治疗肺疾病的方法
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
NZ548300A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
CN101031568A (zh) * 2004-06-23 2007-09-05 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2007056151A2 (en) * 2005-11-03 2007-05-18 Irm Llc Protein kinase inhbitors
WO2008094208A2 (en) * 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2009158587A1 (en) * 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2010043981A1 (en) 2008-10-14 2010-04-22 Activaero Gmbh Method for treatment of copd and other pulmonary diseases
FR2943058B1 (fr) * 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
US20120263715A1 (en) * 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
JP2013525283A (ja) * 2010-04-06 2013-06-20 フレッド ハッチンソン キャンサー リサーチ センター ＭＹＣ駆動型腫瘍細胞の成長および／または増殖を阻害するためのカゼインキナーゼ１εアイソフォームのインヒビターを同定および使用するための方法
CZ2012538A3 (cs) 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
JP5990862B2 (ja) 2012-10-01 2016-09-14 国立研究開発法人科学技術振興機構 承認予測装置、承認予測方法、および、プログラム
EP3102192A2 (en) 2014-02-03 2016-12-14 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of casein kinase i inhibitors for depleting stem cells
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
JP2016193861A (ja) 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
WO2017083971A1 (en) 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
WO2018081575A1 (en) 2016-10-28 2018-05-03 University Of Utah Research Foundation Methods and compositions for identifying and treating patients with small cell lung cancer
AU2018262108A1 (en) 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
WO2020049190A1 (en) 2018-09-09 2020-03-12 Qanatpharma Gmbh Use of casein kinase 1 inhibitors for treating vascular diseases

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103240A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1)
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101616925A (zh) * 2007-02-02 2009-12-30 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途
CN102686580A (zh) * 2009-10-28 2012-09-19 美国辉瑞有限公司 用作酪蛋白激酶抑制剂的咪唑衍生物
WO2012080727A4 (en) * 2010-12-14 2012-10-26 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
CN103298460A (zh) * 2010-12-14 2013-09-11 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
EP2589385A1 (en) * 2011-11-03 2013-05-08 Fundación Centro Nacional de Investigaciones Oncológicas Triple combination for the treatment of cancer
WO2014018691A1 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
CN103784451A (zh) * 2012-10-31 2014-05-14 无锡蕾明视康科技有限公司 一种治疗抑郁症的药物
WO2014100533A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
WO2014100540A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors

Also Published As

Publication number Publication date
US10722513B2 (en) 2020-07-28
FI3273955T3 (fi) 2025-12-12
CN113350353A (zh) 2021-09-07
WO2016149756A1 (en) 2016-09-29
EP3273955B1 (en) 2025-11-12
JP6827948B2 (ja) 2021-02-10
EP3273955A1 (en) 2018-01-31
US11975005B2 (en) 2024-05-07
US20200345740A1 (en) 2020-11-05
US20180071291A1 (en) 2018-03-15
EP4591936A3 (en) 2025-10-15
EP4591936A2 (en) 2025-07-30
EP3273955A4 (en) 2019-05-01
US20240245690A1 (en) 2024-07-25
CN113350352A (zh) 2021-09-07
CN107847480A (zh) 2018-03-27
JP7169693B2 (ja) 2022-11-11
JP2021073232A (ja) 2021-05-13
CN113350352B (zh) 2024-09-10
US11564925B2 (en) 2023-01-31
US20230146291A1 (en) 2023-05-11
JP2018509438A (ja) 2018-04-05

Similar Documents

Publication Publication Date Title
JP7169693B2 (ja) 呼吸器疾患の治療
AU2011278096B2 (en) Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators
CN107998109A (zh) 药物组合物
US20230147683A1 (en) Treatment
JP2022520990A (ja) 呼吸器疾患の治療の方法
CN102803285A (zh) 包含甾体[3，2-c]吡唑衍生物和第二药物活性化合物的药物组合物
AU2019374731A1 (en) Compounds and compositions for the treatment of respiratory diseases
JP2023134493A (ja) 呼吸器疾患の治療のための化合物
HK40058742A (en) Treatment of respiratory diseases
HK40059876A (en) Treatment of respiratory diseases
CN108926707B (zh) Pf4的抗rsv应用
HK40058742B (zh) 呼吸性疾病的治疗
KR20230116786A (ko) 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
HK40023875B (en) Compounds for the treatment of respiratory diseases
HK40023875A (en) Compounds for the treatment of respiratory diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231221

Address after: Vitoria Australia

Patentee after: Tianli Biotechnology Private Ltd.

Address before: Vitoria Australia

Patentee before: THE University OF MELBOURNE